Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Rakovina Therapeutics Inc (RKV.VN)

Rakovina Therapeutics Inc (RKV.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 6,285
  • Shares Outstanding, K 69,830
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,791 K
  • 60-Month Beta 0.16
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.45
Trade RKV.VN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.04
  • Most Recent Earnings $-0.01 on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.070 +28.57%
on 03/27/24
0.135 -33.33%
on 03/28/24
+0.020 (+28.57%)
since 03/26/24
3-Month
0.005 +1,700.00%
on 02/26/24
0.135 -33.33%
on 03/28/24
unch (unch)
since 01/26/24
52-Week
0.005 +1,700.00%
on 02/26/24
0.160 -43.75%
on 05/12/23
-0.060 (-40.00%)
since 04/25/23

Most Recent Stories

More News
Stocks in play: Rakovina Therapeutics Inc.

Will be hosting an informational webinar on Wednesday, April 3. Rakovina Therapeutics Inc. shares V.RKV ...

RKV.VN : 0.090 (unch)
Rakovina Therapeutics Announces Results from Annual General Meeting

VANCOUVER, British Columbia, June 23, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”), a biopharmaceutical company...

RKV.VN : 0.090 (unch)
Rakovina Therapeutics Inc. Announces Q1 2022 Financial Results and Provides Corporate Update

VANCOUVER, British Columbia, May 26, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company...

RKV.VN : 0.090 (unch)
Rakovina Therapeutics Inc. Announces 2021 Financial Results and Provides Corporate Update

VANCOUVER, British Columbia, April 27, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company...

RKV.VN : 0.090 (unch)
InvestmentPitch Media Video Discusses Rakovina Therapeutics and its Presentation of Preclinical Data Supporting Potential Broad Anticancer Activity of kt-4000 Series at the American Association of Cancer Research Annual General Meeting

VANCOUVER, British Columbia, April 14, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV:RKV), a biopharmaceutical company committed to advancing...

RKV.VN : 0.090 (unch)
Rakovina Therapeutics Presents Preclinical Data Supporting Potential Broad Anticancer Activity of kt-4000 Series at the American Association of Cancer Research (AACR) Annual General Meeting

VANCOUVER, British Columbia, April 12, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company...

RKV.VN : 0.090 (unch)
Rakovina Therapeutics to Present Abstract at the 2022 AACR Special Conference – Sarcomas

Company will highlight new data with kt-3000 lead candidates as a potential treatment for Ewing sarcoma...

RKV.VN : 0.090 (unch)
Rakovina Therapeutics to Present Abstract at the 2022 Annual Meeting of the American Association of Cancer Research (AACR)

VANCOUVER, British Columbia, March 09, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company...

RKV.VN : 0.090 (unch)
Rakovina Therapeutics Inc. to Present at Biotech Showcase 2022

VANCOUVER, British Columbia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV:RKV) (“the Company”), a biopharmaceutical company...

RKV.VN : 0.090 (unch)
Rakovina Therapeutics Announces Non-dilutive Financial Contributions to Support Lead Optimization of Novel Anti-cancer Agents

VANCOUVER, British Columbia, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company...

RKV.VN : 0.090 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Rakovina Therapeutics Inc is engaged in drug discovery research, preclinical and clinical development, and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field. Its oncology pipeline has the potential to deliver biomarker-driven...

See More

Key Turning Points

3rd Resistance Point 0.090
2nd Resistance Point 0.090
1st Resistance Point 0.090
Last Price 0.090
1st Support Level 0.090
2nd Support Level 0.090
3rd Support Level 0.090

See More

52-Week High 0.160
Fibonacci 61.8% 0.101
Last Price 0.090
Fibonacci 50% 0.082
Fibonacci 38.2% 0.064
52-Week Low 0.005

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar